Results 221 to 230 of about 104,183 (265)

Resistance to cisplatin.

Anti-cancer drug design, 1999
Resistance to cis-diamminedichloroplatinum(II) (cisplatin), a DNA damaging agent, is a major obstacle for its clinical effectiveness. Multiple mechanisms may be involved in cisplatin resistance. Frequently cited mechanisms include reduced accumulation, elevated levels of glutathione (GSH) and metallothionein, and enhanced DNA repair.
S, Akiyama, Z S, Chen, T, Sumizawa, T, Furukawa   +3 more
openaire   +1 more source

Overcoming cisplatin resistance in chemotherapy by biomineralization

Chemical Communications, 2013
Nano-solidified intermedias (NSI) of cisplatin were prepared via biomineralization and applied to reverse the drug resistance of cancers in vitro and in vivo by an alternative internalization pathway.
Wei, Chen, Yun, Xiao, Xueyao, Liu, Yanhong, Chen, Jiaojiao, Zhang, Xurong, Xu, Ruikang, Tang   +6 more
openaire   +2 more sources

The role of microRNA in cisplatin resistance or sensitivity

Expert Opinion on Therapeutic Targets, 2020
Cisplatin is a chemotherapy drug that has been used to treat a number of cancers for decades, and is still one of the most commonly used anti-cancer agents. However, some patients do not respond to cisplatin while other patients who were originally sensitive to cisplatin eventually develop chemoresistance, leading to treatment failure or/and tumor ...
Shanshan, Wang, Ming-Yue, Li, Yi, Liu, Alexander C, Vlantis, Jason Yk, Chan, Lingbin, Xue, Bao-Guang, Hu, Shucai, Yang, Mo-Xian, Chen, Shaoming, Zhou, Wei, Guo, Xianhai, Zeng, Shuqi, Qiu, C Andrew, van Hasselt, Michael Cf, Tong, George G, Chen   +15 more
openaire   +2 more sources

Mechanisms of acquired resistance to cisplatin

1994
Since the discovery of the antitumor activity in rodents of cisplatin (cis-diamminedichloroplatinum(II)) in 1968 [1], the use of this drug in treating human disease has grown to the point where it is now one of the most widely used antineoplastics. Cisplatin has an established role in the treatment of testicular, ovarian, bladder, germ cell, and head ...
openaire   +2 more sources

Tumour resistance to cisplatin: a modelling approach

Physics in Medicine and Biology, 2004
Although chemotherapy has revolutionized the treatment of haematological tumours, in many common solid tumours the success has been limited. Some of the reasons for the limitations are: the timing of drug delivery, resistance to the drug, repopulation between cycles of chemotherapy and the lack of complete understanding of the pharmacokinetics and ...
Marcu, L., Bezak, E., Olver, I., Van Doorn, T.   +3 more
openaire   +3 more sources

Resistance to cisplatin: How to deal with the problem?

European Journal of Cancer and Clinical Oncology, 1990
SINCE its introduction in clinical practice, cisplatin [cis-diamminedichloroplatinum( II), CDDP] has become one of the most important drugs for treating solid tumors. CDDP-based chemotherapy has clearly improved the response rate for treatment of testicular, ovarian and small cell lung tumors.
J L, Canon, Y, Humblet, M, Symann
openaire   +2 more sources

IN VITRO MODULATION OF CISPLATIN RESISTANCE BY CYTOKINES

Cytokine, 1999
We have previously demonstrated that treatment of wild-type (wt) T98G malignant glioma cells with Cisplatin (CDDP) led to a resistant phenotype. It has been demonstrated that interleukin 1 (IL-1) potentiates the cytotoxic effect of CDDP and that IL-6 decreases cytotoxicity by inhibition of apoptosis in cancer cells. Here we examined the influence of IL-
H, Poppenborg, M M, Knüpfer, H J, Galla, J E, Wolff   +3 more
openaire   +2 more sources

The roles of copper transporters in cisplatin resistance

Cancer and Metastasis Reviews, 2007
Platinum-based antitumor agents have been effective in the treatments of many human malignancies but the ultimate success of these agents is often compromised by development of drug resistance. One mechanism associated with resistance to platinum drugs is reduced intracellular accumulation owing to impaired drug intake, enhanced outward transport, or ...
Macus Tien, Kuo, Helen H W, Chen, Im-Sook, Song, Niramol, Savaraj, Toshihisa, Ishikawa   +4 more
openaire   +2 more sources

Mechanisms of resistance to cisplatin and alkylating agents

1989
All too often, human solid tumors follow a pattern of initial sensitivity to chemotherapy manifested by a decrease of tumor burden followed by a loss of sensitivity to chemotherapy and by tumor regrowth [1]. This sequence of events is attributed to the presence of a subset of cells in the original tumor that are resistant at the onset of therapy and/or
T C, Hamilton, G M, Lai, M L, Rothenberg, A T, Fojo, R C, Young, R F, Ozols   +5 more
openaire   +2 more sources

Cross-resistance to cisplatin in cells with acquired resistance to copper

Cancer Chemotherapy and Pharmacology, 2004
Cells selected for resistance to cisplatin (DDP) demonstrate cross-resistance to copper (Cu) suggesting one or more common mechanisms of cellular defense. We sought to determine whether cells selected for resistance to Cu are cross-resistant to DDP.Parental HuH7 human hepatoma cells and the CuR27 Cu-resistant subline were compared for sensitivity to Cu
Roohangiz, Safaei, Kuniyuki, Katano, Goli, Samimi, Wiltrud, Naerdemann, Jennifer L, Stevenson, Myriam, Rochdi, Stephen B, Howell   +6 more
openaire   +2 more sources